Immunic to participate in investor and scientific conferences in september

New york , sept. 4, 2025 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in september: september 8-10: h.c.
IMUX Ratings Summary
IMUX Quant Ranking